æè¿ãäžè¬ç€Ÿå£æ³äººæ¥æ¬ãªãŒããã¡ãžãŒã³ã³ãœãŒã·ã¢ã ã«ãããªãŒããã¡ãžãŒèªèšŒããŒã¯ãä»ããååãæµéããããã«ãªããå¥åº·é£åãµããªã¡ã³ãã«ããããªãŒããã¡ãžãŒæŽ»æ§ãžã®æ³šç®åºŠãäžãã£ãŠããŠããŸãã
ãã®ãªãŒããã¡ãžãŒã®ååã«é¢ããŠã¯ãåŒç€Ÿã®å ŽåãNMNãšã®çµã¿åããã«ããªãŒããã¡ãžãŒçŽ æãçšããããããšã倧å€æ°ã§ããã
äžæ¹ãããå幎ãåžå Žã§ã¯ãã¶ã¯ãç±æ¥ãŠããªãã³ãªã©ãNMN以å€ã®æåã§ãã泚ç®åºŠãäžããã€ã€ãããŸãã
ãããããNMNããªãŒããã¡ãžãŒæŽ»æ§ãããããããªãïŒ ãšæãããŸããNMNïŒãªãŒããã¡ãžãŒçŽ æã®æ¢åååã¯ããªãŒããã¡ãžãŒæŽ»æ§ãæåŸ ã§ããã®ãïŒãšããç¹ãæ°ã«ãªããç§ã®æ¹ã§ã調æ»ããŠã¿ãŸããã
NMNãã以äžã®æç®ã§ããªãŒããã¡ãžãŒæŽ»æ§ã確èªãããŠããŸããïŒ
ãŸããè©ŠéšããŠã¿ãªããšããããŸããããNMNãé åããååã¯ãå€ããNMNé«é åã§ããããããªãŒããã¡ãžãŒæŽ»æ§ã確èªãããã®ã§ã¯ãªããïŒãšäºæž¬ãããŸãã
ä»åã®èª¿æ»ã§ãå匷ã«ãªã£ãã®ã¯ããªãŒããã¡ãžãŒã¬ãã«ãå¢åŒ·ãããã¡ã«ããºã ã
ãµãŒãã¥ã€ã³ãšãå¯æ¥ãªé¢ä¿ã§ããããšããããç解ã§ããŸããã
ä»åŸãã¢ã«ããã€ããŒåèªç¥çã«å¯Ÿããå¹æã®æ€èšŒãå¢ããŠããã ãããªããšæããŸãããããã§ã®æ€èšŒããè¿ãå°æ¥ãè¡ããããããããªãã
ãŸããéåããŠãã人ã¯ãã¢ã«ããã€ããŒåèªç¥çãå°ãªãçç±ãç解ã§ããŸããã
空æã®é«éœ¢ãªå çæ¹ã®å€ãã¯ããšãŠãå æ°ã§è¡æãªçç±ãªã®ã§ãããã
ã¡ãªã¿ã«ãåŒç€Ÿã¯ãNMNãšãžãªã¹ã²ãã³å æ¥äœã®èšèšãå€ãã®ã§ããããã®èšèšã¯ãè³ã«ãšã£ãŠããéåžžã«è¯ãèšèšã§ããããšãããããŸããã
äžæ¹ãããã§ã®æ€èšŒã¯ãæªã ãã£ããè¡ãããŠããªãé åã®ç 究ã§ããããŸãã
ä»åŸãããèšåºè©Šéšçãè¡ããããªãŒããã¡ãžãŒæŽ»æ§ã«ãã£ãŠæ§ã ãªæå¹æ§ã瀺ãããããšã楜ãã¿ã§ãã
ãè¿œèš19:15ã
åŒç€Ÿã®ãªãŒããã¡ãžãŒçŽ æã®ããŒãžã«ããNMNã®å 容ãè¿œèšããŸããã
åé ã®ãªãŒããã¡ãžãŒèªèšŒããŒã¯ã®èŠæãå¢ããŠãããã§ãããã»ã»ã»ã
äžåœåãååã«ã¯ãç¹ã«è¯ããããããªãã
ãã®ãªãŒããã¡ãžãŒã®ååã«é¢ããŠã¯ãåŒç€Ÿã®å ŽåãNMNãšã®çµã¿åããã«ããªãŒããã¡ãžãŒçŽ æãçšããããããšã倧å€æ°ã§ããã
äžæ¹ãããå幎ãåžå Žã§ã¯ãã¶ã¯ãç±æ¥ãŠããªãã³ãªã©ãNMN以å€ã®æåã§ãã泚ç®åºŠãäžããã€ã€ãããŸãã
ãããããNMNããªãŒããã¡ãžãŒæŽ»æ§ãããããããªãïŒ ãšæãããŸããNMNïŒãªãŒããã¡ãžãŒçŽ æã®æ¢åååã¯ããªãŒããã¡ãžãŒæŽ»æ§ãæåŸ ã§ããã®ãïŒãšããç¹ãæ°ã«ãªããç§ã®æ¹ã§ã調æ»ããŠã¿ãŸããã
NMNãã以äžã®æç®ã§ããªãŒããã¡ãžãŒæŽ»æ§ã確èªãããŠããŸããïŒ
Long-term treatment of Nicotinamide mononucleotide improved age-related diminished ovary reserve through enhancing the mitophagy level of granulosa cells in mice
ãã³ãã³ã¢ããã¢ããã¯ã¬ãªããã®é·ææ²»çã¯ãããŠã¹ã®é¡ç²è现èã®ãã€ããã¡ãžãŒã¬ãã«ãé«ããããšã§ãå 霢ã«äŒŽãåµå·£äºåèœã®æžå°ãæ¹åãã
èŠæšïŒGoogle翻蚳ïŒ
åµå·£ã®èåã¯ãåµæ¯çŽ°èã®è³ªã®äœäžã«ãããé«éœ¢å¥³æ§ã®çæ®ã«é¢ããå¥åº·ã«åœ±é¿ãåãŒããŸãããããã¯ããã³ã³ããªã¢ã®æ©èœäžå šãšå¯æ¥ã«é¢ä¿ããŠããŸãã ãã³ãã³ã¢ãã ã¢ããã¯ã¬ãªãã (NMN) ã¯ãNAD+ ã®åé§äœãšããŠãããŠã¹ã®ããã³ã³ããªã¢ä»£è¬ãå¹æçã«å¶åŸ¡ããŸãã ããããå 霢ã«äŒŽãåµå·£äºåèœã®æžå°ã®æ¹åã«ãããNMNã®åœ¹å²ã¯ãŸã 解æãããŠããªãã æ¬ç 究ã§ã¯ã4ã8ã12ã24ã40é±éœ¢ã®éICRããŠã¹ãæ¡åãã40é±éœ¢ããŠã¹(60WN)ã«NMNã20é±éæäžããå¯Ÿç §çŸ€ã«ã¯NMNãæäžããã æ°ŽïŒ60WCïŒã ãŸããçåŸ40é±ã®ããŠã¹ã«NMNã20é±éæäžãããšãçºæ åšæã®ç¶æ ãå åæ³æ©èœãæ¹åããããšãšãã«ãèåšæ§é ã«å¯Ÿããæèåå¹æãæççå¹æã瀺ãããããšãçºèŠããã 60WN矀ã®åµå·£ã®åå§åµèãäžæ¬¡åµèãäºæ¬¡åµèãèç¶åµèããã³é»äœã®æ°ã¯ã60WC矀ã®ãã®ãšæ¯èŒããŠææã«å¢å ããã ããã«ãåµå·£ã® P16 ã®ã¿ã³ãã¯è³ªããã³éºäŒåçºçŸã¯ã60WC ã°ã«ãŒãããã 60WN ã°ã«ãŒãã§ææã«æžå°ããŸããã NMNã®20é±éã®æäžåŸã®é¡ç²è现èã«ãããããã³ã³ããªã¢çåæããªãŒããã¡ãžãŒã¬ãã«ãããã³ãããã¢ãŒãŒæŽ»æ§ã¯å¢åŒ·ãããŸããã ä»åã®çµæã¯ãNMNãé·ææ²»çã«ãã£ãŠæžå°ããåµå·£äºåèœãæãå¯èœæ§ãæã£ãŠããããšã瀺ããŠãããé¡ç²è现èã®ãã€ããã¡ãžãŒã¬ãã«ãé«ããããšã«ããæåµå·£èåã«ãããNMNã®åœ¹å²ãæ¢æ±ããããã®åºç€ãæäŸããã
J Nutr Biochem. 2022:101:108911.
Effect of Exercise and Oral Niacinamide Mononucleotide on Improving Mitochondrial Autophagy in Alzheimerâs Disease
ã¢ã«ããã€ããŒç ã«ãããããã³ã³ããªã¢ãªãŒããã¡ãžãŒã®æ¹åã«å¯Ÿããéåãšçµå£ãã€ã¢ã·ã³ã¢ããã¢ããã¯ã¬ãªããã®å¹æ
èŠæšïŒGoogle翻蚳ïŒ
çµå£ãã€ã¢ã·ã³ã¢ãã ã¢ããã¯ã¬ãªãã (NMN) ãšæé žçŽ éåã¯ãäœå ã®ãã€ã¢ã·ã³ã¢ããã¢ããã³ ãžãã¯ã¬ãªãã (NAD+) ã匷åããããšã瀺ãããŠããŸãã NAD+ ã¯äœå ã§éèŠãªåœ¹å²ãæãããŠããã代è¬çµè·¯ãDNA 修埩ãã¯ãããã³ãªã¢ããªã³ã°ã现èèåãå ç«çŽ°èæ©èœãªã©ãå€ãã®éèŠãªçŽ°èæ©èœã«çŽæ¥çããã³éæ¥çã«åœ±é¿ãäžããå¯èœæ§ããããŸãã NAD+ã®ã¬ãã«ã¯å 霢ãšãšãã«åŸã ã«æžå°ããããšã¯æ³šç®ã«å€ããŸãã NAD+ ã¬ãã«ã®äœäžã¯ãèªç¥æ©èœäœäžãããã代è¬æ§çŸæ£ããµã«ã³ããã¢ãè匱ãªã©ãå 霢ã«äŒŽãå€ãã®çŸæ£ãšå æé¢ä¿ããããšèããããŠããŸãã èåã«é¢é£ããå€ãã®ç æ°ã¯ãNAD+ ã¬ãã«ãå埩ããããšã§é²è¡ãé ãããããé転ããããããããšãã§ããŸãã ããšãã°ãAPP/PS1 ããŠã¹ã® NAD+ ã¬ãã«ãå¢å ãããããã®çµå£ NMN ãŸãã¯éåã¯ãããã³ã³ããªã¢ ãªãŒããã¡ãžãŒãæ¹åããããšã蚌æãããŠããŸãããçŸåšãçµå£ NMN ãšéåãçµã¿åãããã¬ãžã¡ã³ã¯ãããŸããã ãã®ã¬ãã¥ãŒã¯ãin vivo ã§ã® NAD+ ã®å¢åŒ·ã«å¯Ÿããçµå£ NMN ã®å¹æãšãæé žçŽ éåã«ãã AD ã«ãããããã³ã³ããªã¢ ãªãŒããã¡ãžãŒç°åžžã®æ¹åã«é¢ããæè¿ã®ç 究ãèŠçŽããŠããã(1) çµå£ NMN ãäœå NAD+ ã¬ãã«ãã©ã®ããã«æ¹åãããã(2) ã«çŠç¹ãåœãŠãŠããŸãã (2) éåãäœå ã® NAD+ å«æéãã©ã®ããã«èª¿ç¯ãããã (3) NAD+ ã®éå掻æ§åãš AMPK ã®é¢ä¿ã (4) SIRT1 ãã©ã®ããã« NAD+ ããã³ AMPK ã«ãã£ãŠå¶åŸ¡ãããPGC-1α ã掻æ§åããŠããã³ã³ããªã¢åæ ã®å€åãéããŠããã³ã³ããªã¢ã®ãªãŒããã¡ãžãŒãåªä»ãããã äžèšã® 4 ã€ã®åŽé¢ã®çµæãèŠçŽããçäœå ã§ã® NAD+ åæãšçµã¿åãããããšã§ãéåãã©ã®ããã«çäœå 㧠NAD+ ã¬ãã«ãäžæãããŠããã³ã³ããªã¢ã®ãªãŒããã¡ãžãŒãåªä»ããã®ããæšè«ããéåãã¢ã«ããã€ããŒç ã劚ãããšããæ°ãã仮説ãææ¡ããããšãã§ããŸãã
Nutrients. 2023;15(13):2851.
Nicotinamide mononucleotide induces autophagy and ferroptosis via AMPK/mTOR pathway in hepatocellular carcinoma
ãã³ãã³ã¢ããã¢ããã¯ã¬ãªããã¯è现èçã«ãããŠAMPK/mTORçµè·¯ãä»ããŠãªãŒããã¡ãžãŒãšãã§ãããŒã·ã¹ãèªå°ãã
èŠæšïŒGoogle翻蚳ïŒ
è现èç (HCC) ã¯äžçäžã§äžè¬çãªæªæ§è «çã§ãã ããã§ã¯ãHCC ã®é²è¡ã«ããããã³ãã³ã¢ãã ã¢ããã¯ã¬ãªãã (NMN) ã®åœ¹å²ã調æ»ããŸããã HCC现èãNMNïŒ125ã250ãããã³500ÎŒMïŒã§åŠçãããã®åŸãHCC现èå ã®ãã³ãã³ã¢ããã¢ããã³ãžãã¯ã¬ãªããïŒNAD+ïŒããã³NADHã¬ãã«ã枬å®ããŠãNAD+/NADHæ¯ãèšç®ããã 现èå¢æ®ãã¢ãããŒã·ã¹ããªãŒããã¡ãžãŒãããã³ãã§ãããŒã·ã¹ã枬å®ãããŸããã AMPK/mTOR ã·ã°ãã«äŒéã®é¢äžã確èªããããã«ãAMPK ãããã¯ããŠã³ããŸããã ããã«ãNMN ã®è «çæå¶å¹æãç°çš®ç§»æ€ã¢ãã«ã§èª¿æ»ããŸããã NMN ãžã®æé²ã¯ãHCC 现èã«ããã NAD+ ã¬ãã«ããã³ NAD+ /NADH æ¯ãçšéäŸåçã«å¢å ãããŸããã NMN åŠçåŸã现èå¢æ®ã¯æå¶ãããŸããããäž¡æ¹ã®çŽ°èæ ªã§ã¢ãããŒã·ã¹ãå¢åŒ·ãããŸããã ããã«ãNMN ã¯çšéäŸåçã«ãªãŒããã¡ãžãŒ/ãã§ãããŒã·ã¹ãå¢åŒ·ããHCC 现èã«ããã AMPK/mTOR çµè·¯ã掻æ§åããŸããã AMPK ããã¯ããŠã³ã«ãããin vitro 㧠NMN ã®åœ±é¿ãéšåçã«å埩ããŸããã ããã«ãNMN æ²»çã¯ããŒãããŠã¹ã®è «çå¢æ®ãæå¶ãããªãŒããã¡ãžãŒ/ãã§ãããŒã·ã¹ã掻æ§åããè «ççµç¹ã®ã¢ãããŒã·ã¹ãšå£æ»ãä¿é²ããŸããã ãã®çµæã¯ãNMN ã AMPK/mTOR ã·ã°ãã«äŒéãä»ããŠãªãŒããã¡ãžãŒãšãã§ãããŒã·ã¹ãèªå°ããããšã«ãããHCC ã®é²è¡ãé»å®³ããããšã瀺ããŠããŸãã NMN 㯠HCC æ²»çã®ææãªè¬å€ãšããŠæ©èœããå¯èœæ§ããããŸãã
Mol Carcinog. 2024;63(4):577-588.
ãŸããè©ŠéšããŠã¿ãªããšããããŸããããNMNãé åããååã¯ãå€ããNMNé«é åã§ããããããªãŒããã¡ãžãŒæŽ»æ§ã確èªãããã®ã§ã¯ãªããïŒãšäºæž¬ãããŸãã
ä»åã®èª¿æ»ã§ãå匷ã«ãªã£ãã®ã¯ããªãŒããã¡ãžãŒã¬ãã«ãå¢åŒ·ãããã¡ã«ããºã ã
ãµãŒãã¥ã€ã³ãšãå¯æ¥ãªé¢ä¿ã§ããããšããããç解ã§ããŸããã
ä»åŸãã¢ã«ããã€ããŒåèªç¥çã«å¯Ÿããå¹æã®æ€èšŒãå¢ããŠããã ãããªããšæããŸãããããã§ã®æ€èšŒããè¿ãå°æ¥ãè¡ããããããããªãã
ãŸããéåããŠãã人ã¯ãã¢ã«ããã€ããŒåèªç¥çãå°ãªãçç±ãç解ã§ããŸããã
空æã®é«éœ¢ãªå çæ¹ã®å€ãã¯ããšãŠãå æ°ã§è¡æãªçç±ãªã®ã§ãããã
ã¡ãªã¿ã«ãåŒç€Ÿã¯ãNMNãšãžãªã¹ã²ãã³å æ¥äœã®èšèšãå€ãã®ã§ããããã®èšèšã¯ãè³ã«ãšã£ãŠããéåžžã«è¯ãèšèšã§ããããšãããããŸããã
äžæ¹ãããã§ã®æ€èšŒã¯ãæªã ãã£ããè¡ãããŠããªãé åã®ç 究ã§ããããŸãã
ä»åŸãããèšåºè©Šéšçãè¡ããããªãŒããã¡ãžãŒæŽ»æ§ã«ãã£ãŠæ§ã ãªæå¹æ§ã瀺ãããããšã楜ãã¿ã§ãã
ãè¿œèš19:15ã
åŒç€Ÿã®ãªãŒããã¡ãžãŒçŽ æã®ããŒãžã«ããNMNã®å 容ãè¿œèšããŸããã
åé ã®ãªãŒããã¡ãžãŒèªèšŒããŒã¯ã®èŠæãå¢ããŠãããã§ãããã»ã»ã»ã
äžåœåãååã«ã¯ãç¹ã«è¯ããããããªãã
- ã«ããŽãªïŒ
- ææ°ç 究ããŒã¿
- 泚ç®ã®åæ
ãã®ããã°ã«ã³ã¡ã³ãããã«ã¯ãã°ã€ã³ãå¿ èŠã§ãã
ãããã°ã¢ãŠã
ãã®èšäºã«ã¯èš±å¯ãŠãŒã¶ããã³ã¡ã³ããã§ããŸããã